These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35841520)

  • 21. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Parkinson's disease: what is the best approach to treatment.
    Hristova AH; Koller WC
    Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.
    Stocchi F; Barone P; Ceravolo R; De Pandis MF; Lopiano L; Modugno N; Padovani A; Pilleri M; Tessitore A; Zappia M
    Ann Med; 2024 Dec; 56(1):2315226. PubMed ID: 38381654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of current and novel levodopa formulations for the treatment of Parkinson's disease.
    Jimenez-Shahed J
    Ther Deliv; 2016; 7(3):179-91. PubMed ID: 26893250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
    Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
    Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging drugs for Parkinson's disease.
    Morgan JC; Sethi KD
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):403-17. PubMed ID: 16939381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
    Hoy SM
    Drugs; 2019 Oct; 79(15):1709-1718. PubMed ID: 31549300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet medical needs in Parkinson's disease.
    Koller WC; Tse W
    Neurology; 2004 Jan; 62(1 Suppl 1):S1-8. PubMed ID: 14718675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.